Abstract
*Dehns, St Bride’s House, 10 Salisbury Square, London, EC4Y 8JD, UK Tel.: +44 20 7632 7200 Fax: +44 20 7353 8895 E-mail: jalbutt@dehns.com On 1 April 2013, the Supreme Court in India dismissed Novartis AG’s appeal against the rejection of their patent application for their anticancer drug Glivec® [1]. The Indian refusal is in contrast with the outcome in almost 40 other countries, where patent protection for the drug has been allowed. If the threshold for obtaining patent protection for a pharmaceutical product is higher in India than in other countries, will this negatively affect the country’s ability to attract R&D and investment in future innovation?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
